DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Ionis - 2 Morgan Stanley - 1 Garadacimab - 1 Citi - 1 Russell - 1 Dan Niles - 1 CNBC's - 1 Niles - 1
Top related locs:
Israel Gaza
Top related orgs:
Citi - 3 Ionis Pharmaceuticals - 3 Biotech - 1 Intellia Therapeutics - 1 CSL - 1 Intellia - 1 CNBC - 1 Russell - 1

Search resuls for: "Ionis Pharmaceuticals"


4 mentions found


☆ Citi names 3 biotech stocks to play a growing $2.9 billion opportunity — giving one about 50% upside
  + stars: | 2024-05-01 | by ( Weizhen Tan | ) www.cnbc.com   time to read: +2 min
The outlook is starting to look bright for biotech stocks, according to some. With markets now expecting the first rate cut to be in September rather than June or July, as previously thought, biotech stocks could start to do well. Biotech encompasses many different areas, but Citi has identified one with a $2.9 billion market — which it says is set for even more growth. It gave CSL a price target of $305, or nearly 11% potential upside. It gave Intellia a price target of $31, or 49% potential upside.
Persons: Morgan Stanley, Garadacimab, Ionis, Citi Organizations: Biotech, Citi, Ionis Pharmaceuticals, Intellia Therapeutics, CSL, Intellia
☆ Wall Street says small-cap stocks are a good bet in a choppy market. Here are the top names
  + stars: | 2023-10-17 | by ( Weizhen Tan | ) www.cnbc.com   time to read: +3 min
Small-cap stocks were on investors' radar last week. The Russell 2000 index turned in five straight days of gains for the first time since mid-July, according to CNBC analysis. "We're in consumer staples stocks and Russell 2000 stocks," said Niles, adding that Pepsi is the fourth-largest holding in his Satori Fund's consumer staples basket. Both Citi and Morningstar said small-cap stocks now look cheaper than the broader market. How to play small-caps One of the more popular ways to invest in small-cap stocks is through the iShares Russell 2000 ETF (IWM).
Persons: Russell, Dan Niles, CNBC's, Niles, David Bailin, Morningstar, Davidson, — CNBC's Michelle Fox, Fred Imbert Organizations: CNBC, Russell, Pepsi, Citi, Citi Global Wealth's, Morningstar Equity Research, Ionis Pharmaceuticals, Screen CNBC Pro Locations: Israel, Gaza
☆ This little-known pharma stock can rally 50%, Citi says
  + stars: | 2023-07-31 | by ( Brian Evans | ) www.cnbc.com   time to read: +1 min
It's time to buy shares of Ionis Pharmaceuticals , according to Citi. The firm upgraded the stock on Monday to buy from neutral and raised its price target to $60 from $36. "Though HAE is a competitive market, Phase II data hints that it could have an attractive product profile and be a meaningful player," Lebowitz said. Given current valuation, we view the risk-reward on Ionis shares as being skewed positive." Lebowitz also highlighted donidalorsen's phase 2 test performance, which underpinned the stock upgrade.
Persons: David Lebowitz, eplontersen, HAE, Lebowitz, donidalorsen, Ionis, Michael Bloom Organizations: Ionis Pharmaceuticals, Citi, AstraZeneca, donidalorsen, Ionis
☆ Morningstar: Buy these 14 cheap stocks that still have room to rally in a bear market
  + stars: | 2022-11-24 | by ( Lisa Kailai Han | ) www.businessinsider.com   time to read: +4 min
Contrary to intutition, bear market rallies may make it tougher for investors to do their jobs. Morningstar shared 14 stocks that are still cheap, despite beating the market. Then, they whittled that list down to the stocks that Morningstar analysts considered undervalued. Finally, Morningstar analysts highlighted AstraZeneca (AZN), noting its strong pipeline and its development of drugs that carry high pricing power. The full list of Morningstar's 14 undervalued bear market stars is below, along with each firm's ticker, sector, bear market return, and price discount.
0 next >>
Total: 4